Podcasts about biotech

Join us for an insightful episode of The Edge of Show as we dive into the world of decentralized AI finance with Ron Bodkin, co-founder and CEO of Theoriq Labs. With over 15 years of experience in applied AI, Ron shares his journey from working at tech giants like Google to pioneering a decentralized AI protocol that empowers autonomous agents to manage capital and execute strategies on-chain.In this episode, we explore:The intersection of AI and blockchain technologyThe importance of decentralization in the future of financeHow Theoriq Labs is leveraging AI agents to enhance DeFi strategiesThe challenges and opportunities in creating a decentralized ecosystemInsights into the future of capital markets and the role of AI agentsWhether you're a crypto enthusiast, a tech innovator, or just curious about the future of finance, this episode is packed with valuable insights and thought-provoking discussions.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Dr. Marissa Russo trained to become a cancer biologist. She spent four years studying one of the deadliest brain tumors in adults and built her entire research career around a simple, urgent goal: open her own lab and improve the odds for patients with almost no shot at survival. In 2024 she applied for an F31 diversity grant through the NIH. The reviewers liked her work. Her resubmission was strong. Then the grant system started glitching. Dates vanished. Study sections disappeared. Emails went silent. When she finally reached a program officer, the message was clear: scrub the DEI language, withdraw, and resubmit. She rewrote the application in ten days. It failed. She had to start over. Again. This time with her identity erased.Marissa left the lab. She found new purpose as a science communicator, working at STAT News through the AAAS Mass Media Fellowship. Her story captures what happens when talent collides with institutional sabotage. Not every scientist gets to choose a Plan B. She made hers count.RELATED LINKSMarissa Russo at STAT NewsNIH F31 grant story in STATAAAS Mass Media FellowshipContact Marissa RussoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Was tun, wenn eine E-Mail das ganze Leben verändern könnte? Dr. Philipp Baaske hat für sein Unternehmen ein Kaufangebot über mehrere hundert Millionen Euro erhalten. Ein Exit, der vieles ermöglichen würde. Und doch hat er das Angebot abgelehnt. In dieser Podcastfolge spreche ich mit dem Gründer von NanoTemper Technologies über diese Entscheidung und über das, was folgt, wenn man sich bewusst gegen das schnelle Geld entscheidet. Heute beschäftigt NanoTemper rund 240 Mitarbeitende an neun Standorten weltweit. Ihre biophysikalischen Messgeräte spielen eine zentrale Rolle in der Entwicklung von mRNA-Impfstoffen. Für seine Arbeit wurde Philipp Baaske mehrfach ausgezeichnet, unter anderem mit dem Deutschen Gründerpreis und dem Deutschen Innovationspreis. Seine Haltung hat er in seinem Buch „The Honorable Entrepreneur“ beschrieben. Unser Gespräch kreist um Fragen, die selten offen gestellt werden: um Verlockung und Verzicht, um Unabhängigkeit, Verantwortung und Vertrauen. Wir sprechen darüber, was Geld ermöglicht und was es nicht lösen kann. Über persönliche Prägungen, über ein starkes „Warum“ und über den Preis und die Chancen, die werteorientiertes Unternehmertum mit sich bringt. Im Gespräch geht es unter anderem um: - die bewusste Entscheidung gegen Venture Capital und für Kundenfinanzierung - die Verlockung des schnellen Geldes und ihre Wirkung auf Unternehmer - Führungskultur jenseits von Schlagworten - schnelles Wachstum, seine Risiken und Lernmomente - den Schritt vom operativen Co-CEO zum Executive Chairman Ein Gespräch über unternehmerische Verantwortung, über Vertrauen – und darüber, was Erfolg bedeuten kann, wenn man ihn nicht nur in Zahlen misst. Ihr findet Philipp auf LinkedIn unter: https://www.linkedin.com/in/philipp-baaske/ und auf seiner Website gibt es den Zugang zum Buch und zu weiteren Informationen: https://www.philippbaaske.com Alle Informationen zu meiner Arbeit findet ihr wie immer unter: www.hannah-panidis.de Und hier begegnet ihr mir meist tagesaktuell: Instagram: https://www.instagram.com/hannahpanidis LinkedIn: https://www.linkedin.com/in/hannah-panidis-55141a145/?originalSubdomain=de Facebook: https://www.facebook.com/HannahPanidisKommunikation/?locale=de_DE

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation, Josh Kriger is joined by Josh Lawler, Cathy Hackl, Nicholas Zaldastani, and Janet Adams as they unpack the global race toward artificial general intelligence (AGI) and why decentralization may be the key to building ethical, transparent, and inclusive AI systems.The discussion dives into agentic AI, decentralized infrastructure, trust networks, data ownership, deepfakes, humanoid robotics, and the growing risks of centralized control. From real-world AI governance challenges to the role blockchain can play in accountability and verification, this episode cuts through the hype and focuses on what actually needs to be built and fixed.If you're building, investing, or simply trying to understand where AI and Web3 are heading next, this conversation offers clear insights from leaders working at the edge of innovation.Watch now and join the conversation shaping the future of intelligence.Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

How can universities become powerful engines of innovation, startups, and economic growth—especially in a challenging funding environment? In this episode, host Elaine Hamm, PhD, sits down with Kimberly Gramm, PhD, MBA, the David & Marion Mussafer Chief Innovation and Entrepreneurship Officer at the Tulane Innovation Institute and Managing Director of Tulane Ventures. Kimberly shares how Tulane is building a comprehensive innovation ecosystem—from early-stage programming and mentorship to venture funding—designed to help researchers, students, and founders translate discovery into real-world impact. Together, they explore what it takes to change institutional culture, scale innovation thoughtfully, and position universities as active investors in the future of biotech and healthcare. In this episode, you'll learn: How universities can support founders and technologies across every stage of the innovation journey, not just at commercialization. Why mentorship, alumni engagement, and listening to stakeholders are critical to building sustainable innovation programs. How strategic venture funds and proof-of-concept investments can accelerate biotech spinouts and regional economic growth. Whether you're a researcher, founder, or innovation leader, this episode offers a behind-the-scenes look at how universities can step up, take risks, and help innovation thrive—even in uncertain times. Links: Connect with Kimberly Gramm, PhD, MBA, and check out Tulane Innovation Institute and Tulane Ventures. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out our previous episode with Kimberly. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

DescriptionWelcome to this episode of The Edge of Show, where we dive into the forces reshaping AI, Web3, and the future of digital trust. We're joined by Sandy Carter to break down the biggest shifts happening right now in AI, blockchain, and digital identity. We get into IBM's $11B Confluent acquisition, how AI agents are already making decisions inside major companies, and why stablecoins just surpassed Visa and Mastercard in global settlement volume.We also cover Sandy's predictions for 2026: the rise of autonomous agents, the trust layer blockchain provides, decentralized robots, and why every company will need real-time verification. Plus, Sandy gives us an inside look at what's next for Unstoppable Domains as identity moves fully on-chain.If you want a clear, no-nonsense breakdown of where the digital economy is actually heading, this episode is it.Tune in now and join the conversation!

Scott Capozza and I could have been cloned in a bad lab experiment. Both diagnosed with cancer in our early twenties. Both raised on dial-up and mixtapes. Both now boy-girl twin dads with speech-therapist wives and a lifelong grudge against insurance companies. Scott is the first and only full-time oncology physical therapist at Yale New Haven Health, which means if he catches a cold, cancer rehab in Connecticut flatlines. He's part of a small, stubborn tribe of providers who believe movement belongs in cancer care, not just after it. We talked about sperm banking in the nineties, marathon training during chemo, and what it means to be told you're “otherwise healthy” when your lungs, ears, and fertility disagree. Scott's proof that survivorship is not a finish line. It's an endurance event with no medals, just perspective.RELATED LINKSScott Capozza on LinkedIn: https://www.linkedin.com/in/scott-capozza-a68873257Yale New Haven Health: https://www.ynhh.orgExercising Through Cancer: https://www.exercisingthroughcancer.com/team/scott-capozza-pt-msptProfiles in Survivorship – Yale Medicine: https://medicine.yale.edu/news-article/profiles-in-survivorship-scott-capozzaFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

India's cotton story was once a global success - yields tripled & exports surged. But over the last few years, India has gone from second largest exporter to net importer of cotton. ThePrint Editor-in-Chief Shekhar Gupta explains reasons behind India's tragic cotton collapse, and breaks down the data over the past few decades. #CutTheClutter Ep 1772----more----Read Harish Damodaran's article here: https://indianexpress.com/article/opinion/columns/why-india-fell-behind-in-the-cotton-race-an-aversion-to-science-and-technology-9912107/

What if we could predict how chemicals affect human lungs without using animals? In this episode of Sounds of Science, Mary McElroy, Head of Discovery Toxicology and Pharmacology at Charles River, joins us to explore a groundbreaking collaboration with MatTek Life Sciences. Together, they're pioneering human-relevant, non-animal models that could revolutionize inhalation toxicology. From 3D lung tissues to computational dosimetry, discover how science is catching its breath and moving toward a safer, more ethical future. Show NotesInhalation Toxicology | Charles River Mini Organs Offer Alternative Method for Predicting Drug Safety and Efficacy Alternative Methods Advancement Project | Charles River Charles River, in Collaboration with MatTek Corporation, Awarded Grant from the Foundation for Chemistry Research and Initiatives to Advance Research Alternatives 

Shares of Ford on the move after the automaker announced a $19.5b write off of its electric vehicle business. What the company is focusing on now, instead. Plus Terns Pharmaceuticals announced positive results for its new cancer drug last week. The CEO joins to lay out next steps for the company.  Fast Money Disclaimer Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

If you've ever checked the ingredients on a baked good, you know how ubiquitous eggs are. They bind, they lift, they emulsify, they hold moisture — they're simply the structural engineers of cookies, cakes, and muffins everywhere. But they're also volatile: prices spike, supply chains break, and for anyone with an egg allergy or who's avoiding eggs for animal welfare or environmental reasons, eggs aren't exactly a welcome ingredient to find on the ingredient deck.  Enter Hadar Ekhoiz Razmovich, CEO and co-founder of Meala FoodTech, an Israeli startup that's figured out how to make peas do what eggs and hydrocolloids do, and has consequently raised several million dollars in venture capital so far. Meala's breakthrough lies in taking simple pea protein and using advanced biotechnology to unlock its hidden abilities — creating a single-ingredient powder that they say can whip, bind, and gel just like an egg in baked goods and alternative meat. No multi-ingredient formulations, no methylcellulose, no animal inputs — just plants doing some biochemical magic.  In this episode, Hadar shares how her background in R&D led her to tackle one of food science's toughest challenges: replacing eggs and hydrocolloids without sacrificing texture, taste, or cost. We talk about how Meala's technology works, what it takes to convince industrial bakeries to swap eggs for peas, and why she believes clean-label ingredients like this are the future of food.  Hadar is not just rethinking what we eat, she and her team are rebuilding the food system from scratch, one cookie, cake, and croissant at a time.  Discussed in this episode  Meals is backed by The Kitchen Food Tech Hub, DSM's venture arm, Milk & Honey Ventures, Lasenor, and EIT.  Our past episode with Milk & Honey Ventures' Beni Nofech.  More on Meala's egg replacer, GroundBaker, is here.  You can see two pending patent applications of Meala's here and here.    Get to know Hadar Ekhoiz Razmovich  Hadar Ekhoiz Razmovich brings over 12 years of leadership experience in the global food industry, with a strong focus on driving innovation and R&D across traditional food sectors. Throughout her career, she has led complex, multidisciplinary projects from early concept development to full commercial launch, consistently bridging technological capabilities with real market needs.  In 2021, she founded Meala FoodTech with a mission to transform the food industry. Under her leadership, Meala is pioneering clean-label functional protein that deliver superior texture, bite, and mouthfeel—without compromise and without undesirable additives. Her work empowers food manufacturers to create simpler, more natural, and better-tasting products, setting a new benchmark for next-generation of food.  Hadar is widely recognized for her strategic vision, deep industry insight, and ability to translate scientific innovation into scalable commercial solutions. 

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Bruce Culleton, M.D., CEO at ProKidney, talks about moving from academic research to industry and the role a key mentor played in his career path. Bruce discusses his experiences as a first-time CEO at ProKidney, a late-stage autologous cell therapy biotech focused on pioneering new treatments for chronic kidney disease (CKD), the benefits of FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, how delaying or avoiding kidney dialysis would be a game-changer for CKD patients, and more.  Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode of Data in Biotech, host Ross Katz sits down with Eshani Galermo, Staff Scientist at SCIEX, to explore the next generation of mass spectrometry in pharma and biopharma. Eshani explains how innovations like the ZenoTOF 8600 are redefining sensitivity, selectivity, and workflow efficiency in bioanalytical chemistry. Discover how high-resolution accurate mass (HRAM) systems are unlocking new capabilities in drug discovery, clinical studies, and regulatory science. What you'll learn in this episode: >> Why traditional mass spectrometry falls short in modern bioanalysis >> How the ZenoTOF 8600 enhances sensitivity and reduces sample volume needs >> The role of high-resolution systems in detecting complex drug metabolites >> How automation tools are streamlining workflows for bioanalytical scientists >> The complementary role of AI and ML in mass spec data analysis Meet our guest Eshani Galermo is a Staff Scientist at SCIEX, where she leads global strategic marketing initiatives for pharma and biopharma quant applications. With deep expertise in bioanalytical chemistry and mass spectrometry, she has held multiple scientific roles across SCIEX, Emery Pharma, and Genentech.  About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Eshani Galermo on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

Welcome to this episode of The Edge of Show, where we dive into the forces reshaping AI, Web3, and the future of digital trust. We're joined by Sandy Carter to break down the biggest shifts happening right now in AI, blockchain, and digital identity. We get into IBM's $11B Confluent acquisition, how AI agents are already making decisions inside major companies, and why stablecoins just surpassed Visa and Mastercard in global settlement volume.We also cover Sandy's predictions for 2026: the rise of autonomous agents, the trust layer blockchain provides, decentralized robots, and why every company will need real-time verification. Plus, Sandy gives us an inside look at what's next for Unstoppable Domains as identity moves fully on-chain.If you want a clear, no-nonsense breakdown of where the digital economy is actually heading, this episode is it.Tune in now and join the conversation!

Networking in biotech doesn't have to feel awkward or transactional. In this episode, Carina shares how giving first is the simplest way to build authentic biotech networking on LinkedIn that actually leads to stronger relationships and better opportunities.If you're an introvert, early-career professional, or making a career change, this is your practical roadmap to connect with confidence.In this episode, you'll learn:Why “give first” makes networking feel easier (and work better)How to add value even if you're early in your career or switching fieldsWhat to say when you feel you've got nothing to offerThe biggest outreach mistakes that make messages feel transactionalSimple LinkedIn actions that build visibility and trust over timeInsights from the Biotech Career Coach community's December networking challenge (and what drove major reach growth)Want support, templates, and challenges to stay consistent?✅ Join the Biotech Career Coach Skool community to connect with peers, access templates, and take part in challenges to grow your LinkedIn presence and your biotech network.Learn more about the Collaboratory Career Hub community and access our free resources:Join our Skool CommunityTake the Free 7-day Interview Sprint ChallengeCheck out our sister podcast: Building BiotechsSend Carina a connection request on LinkedIn!Stay connected with us:

“Drug development has become slower and more expensive despite all the new technology,” says Eric Hughes, executive vice president of Global R&D and chief medical officer of Teva Pharmaceutical. “That’s caused by increased regulatory scrutiny, more needs for quality, more needs for real treatment effects. But we’re in a unique position where we can stay really hyper-focused on what we’re doing. I’m on calls every week driving teams on enrollment studies, looking at data as quickly as possible, being able to pivot on things that I see that they’re bringing to me and being able to make decisions very rapidly and drive programs forward. I think that that ability to be like a biotech in a very large company is part of the secret sauce of what Teva’s doing right.” In this episode of the Vanguards of Health Care podcast, Hughes sits down with Bloomberg Intelligence analyst Ann-Hunter van Kirk for an in-depth interview about how the legacy generic manufacturer has built an R&D engine by replacing silos with a matrix structure, building partnerships and capitalizing on speed with AI.See omnystudio.com/listener for privacy information.

Join us for an insightful episode of The Edge of Show as we dive into the world of decentralized AI finance with Ron Bodkin, co-founder and CEO of Theoriq Labs. With over 15 years of experience in applied AI, Ron shares his journey from working at tech giants like Google to pioneering a decentralized AI protocol that empowers autonomous agents to manage capital and execute strategies on-chain.In this episode, we explore:The intersection of AI and blockchain technologyThe importance of decentralization in the future of financeHow Theoriq Labs is leveraging AI agents to enhance DeFi strategiesThe challenges and opportunities in creating a decentralized ecosystemInsights into the future of capital markets and the role of AI agentsWhether you're a crypto enthusiast, a tech innovator, or just curious about the future of finance, this episode is packed with valuable insights and thought-provoking discussions.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Welcome to this episode of The Edge of Show recorded live at the Future of Money, Governance, and the Law (FOMGL) event in Washington, D.C. In this conversation,Josh Kriger is joined by Craig Salm, Ryan VanGrack, Kyle Hauptman, and Jon Ungerland for a candid breakdown of the rapidly evolving world of FinTech, blockchain, and digital assets. Together, they dig into regulatory clarity, the rise of DeFi, shifting consumer behaviors, and what recent policy moves mean for the future of money.Key Highlights:How regulatory uncertainty impacts builders, investors, and institutionsThe rise of DeFi and new expectations around decentralized servicesWhat recent SEC changes signal for digital assetsHow local financial institutions adapt to new money networksPredictions for the future of money and innovation in U.S. financeThis episode is for policymakers, innovators, and industry leaders who want to explore how emerging technologies are reshaping finance.Support us through our Sponsors! ☕

Lab-made eggs. Lab-made sperm.Children engineered, screened, and selected.Marriage optional. Mothers and fathers optional.Embryos discarded like products.IVG: the new horror of Bio-Tech

Synopsis: This episode is proudly sponsored by Quartzy. What happens when engineering discipline, business pragmatism, and breakthrough immunology collide? In this episode of Biotech 2050, host Alok Tayi sits down with Jay Hartenbach, President & COO of Diakonos Oncology, to unpack one of the most unconventional—and promising—approaches in cancer immunotherapy today. Jay traces his journey from biomedical engineering into biotech operations, sharing how Diakonos was built outside the traditional venture playbook and why the company chose to tackle two of the most punishing cancers first: glioblastoma and pancreatic cancer. He reveals how Diakonos' dual-loading dendritic cell platform creates an exponentially stronger immune response—essentially tricking the body into launching a viral-level attack against cancer. From capital-efficient clinical execution to nontraditional fundraising and early signs of durable patient responses, this conversation offers a rare, behind-the-scenes look at how bold science, disciplined operations, and relentless persistence can reshape what's possible in oncology. Biography: Jay Hartenbach is a distinguished leader in the biotechnology and wellness sectors, known for his passionate commitment to advancing innovative healthcare solutions and transforming patient outcomes. He currently serves as President and Chief Operating Officer at Diakonos Oncology, where he is leading the team through the development and clinical advancement of pioneering immunotherapies targeting some of the most difficult-to-treat cancers, including glioblastoma and pancreatic ductal adenocarcinoma.​ Since joining Diakonos Oncology, Jay has been instrumental in achieving significant milestones such as attaining FDA Fast Track and Orphan Drug Designation for the company's lead candidate, DOC1021, securing greater than $30 million in financing, and establishing research collaborations with leading cancer centers to advance the clinical trials of the company's novel dendritic cell vaccine platform. Before his role at Diakonos, Jay co-founded Medterra, a globally recognized wellness company that set industry standards for quality and innovation, and where he continues to serve as Chairman of the Board, shaping high-level strategic direction. He also co-founded Perland Pharmaceuticals, an early-stage biotech firm focused on developing therapies for arthritis conditions, and has held leadership and board advisory roles across several life sciences ventures.​ Jay holds a degree in biomedical engineering from the University of Miami and a Master of Engineering Management from Duke University, grounding his entrepreneurial leadership with scientific expertise.

What if your alumni network could help fuel the next generation of biotech startups? In this episode, host Elaine Hamm, PhD, sits down with Evan Nicoll, MBA, and Patrick Hernandez of 1834 Ventures, a new investment fund created by Tulane alumni, for founders with Tulane DNA. They share how their alumni-powered model is helping to close regional funding gaps, strengthen emerging biotech ecosystems, and support founders through trust-driven, relationship-first investing. From navigating today's tough fundraising climate to understanding what really catches an investor's eye, this conversation offers practical lessons for founders, universities, and anyone building innovation communities. In this episode, you'll learn: How alumni networks can become powerful engines for venture funding, mentorship, and deal flow. What investors are really looking for in early biotech pitches, and why trust, clarity, and curiosity matter more than perfection. Why founders should embrace relationship-building over rapid-fire pitching, and how regional markets like Louisiana can attract coastal investors. Tune in to discover how connection-driven investing is helping shape the next chapter of biotech growth across the Gulf South — and how you can be part of it. Links: Connect with Evan Nicoll, MBA, and Patrick Hernandez, and check out 1834 Ventures. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out Cadenza Bio and the book The Speed of Trust. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Dr. MaryAnn Wilbur trained her whole life to care for patients, then left medicine behind when it became a machine that punished empathy and rewarded throughput. She didn't burn out. She got out. A gynecologic oncologist, public health researcher, and no-bullshit single mom, MaryAnn walked straight off the cliff her career breadcrumbed her to—and lived to write the book.In this episode, we talk about what happens when doctors are forced to choose between their ethics and their employment, why medicine now operates like a low-resource war zone, and how the system breaks the very people it claims to elevate. We cover moral injury, medical gaslighting, and why she refused to lie on surgical charts just to boost hospital revenue.Her escape plan? Tell the truth, organize the exodus, and build something that actually works. If you've ever wondered why your doctor disappeared, this is your answer. If you're a clinician hiding your own suffering, this is your permission slip.RELATED LINKSMaryAnn Wilbur on LinkedInMedicine ForwardClinician Burnout FoundationThe Doctor Is No Longer In (Book)Suck It Up, Buttercup (Documentary)FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Fueled by cancer, obesity and cardiovascular deals, $1 billion-plus takeouts in biotech are at their highest level in a decade with three weeks to go in the year. On the latest BioCentury This Week, BioCentury's analysts discuss the rise in large M&A deals and what the trends among the 37 acquisitions say about biopharma dealmaking.The analysts assess first-in-human in vivo CAR T data at the American Society of Hematology meeting from Kelonia Therapeutics, which showcase the promise of the modality and justify the growing pipeline. They also break down readouts from Praxis in developmental and epileptic encephalopathy from the American Epilepsy Society Annual Meeting and from Novo Nordisk, which presented full data at the Clinical Trials on Alzheimer's Disease meeting on semaglutide's failure to treat Alzheimer's disease.Washington Editor Steve Usdin analyzes a roller-coaster week at FDA in which Richard Pazdur resigned as director of FDA's Center for Drug Evaluation and Research and Tracy Beth Høeg became acting CDER director, a move that Usdin says will prompt staff departures, ease restraints on FDA leadersView full story: https://www.biocentury.com/article/657781#BiotechMA #CARTTherapy #EpilepsyResearch #AlzheimersDisease #FDA02:37 - Biotech M&A06:39 - In vivo CAR T10:08 - Semaglutide for Alzheimer's16:17 - Praxis22:11 - FDATo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Andreas Munk Holm opens the episode by introducing Charles Dunn, Principal at SV Health Investors, and Ruth McKernan, CBE and Operating Partner at SV Health, former CEO of Innovate UK. SV Health is a transatlantic healthcare specialist with a focus on company creation and full-spectrum biotech investing. Notable wins include the exit of SV-created EyeBio to Merck & Co for up to $3bn including $1.3bn upfront, and the recent launch of SV's newest company creation Driag Therapeutics, a UK-based neuropsychiatry company, which recently announced its $140m Series A financing.SV Health's approach blends early-stage company creation with later-stage venture investment. Charles emphasizes that this structure allows:Diversified risk for LPs: Early-stage opportunities carry higher risk but higher upside; later-stage investments provide more stability.Learning across stages: Experience in late-stage investing informs early-stage decision-making, and vice versa.Flexible company formation: SV Health creates companies across different development stages, sometimes even after Phase 1 data exists, as with Draig Therapeutics.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of compelling advancements and challenges that are shaping this dynamic industry.Pfizer has recently unveiled phase 3 results for its hemophilia drug Hympavzi, positioning it as a formidable competitor against Sanofi's Qfitlia and Novo Nordisk's Alhemo. The data suggests Hympavzi offers robust efficacy, potentially revolutionizing hemophilia treatment and enhancing patient outcomes significantly. This development is not just about competition; it represents a critical stride forward in patient care for those affected by this debilitating condition.UCB plans to seek regulatory approval for Fintepla to treat an additional epileptic disorder following positive phase 3 trial results in patients with CDKL5 deficiency disorder. This decision reflects promising results and could offer new hope to patients with limited treatment options, further cementing Fintepla's position in epilepsy management.Gene therapy continues to shine with CSL's Hemgenix demonstrating sustained long-term benefits. After five years of follow-up, a single dose has reduced annualized bleeding rates by an impressive 90% in hemophilia B patients within the Hope-B study. Such long-term efficacy highlights gene therapy's transformative potential, offering lasting improvements in quality of life for patients with genetic disorders.Regulatory frameworks are also evolving, as evidenced by the CDC's Advisory Committee on Immunization Practices (ACIP) voting to modify hepatitis B vaccine guidance for newborns. This decision advocates an individualized approach, sparking debate over vaccination strategies, which reflects the complexities and delicate balance required in public health policies today.Regeneron is making strides to simplify treatment regimens for T-cell engagers Lynozyfic and Ordspono. By reducing regimen complexity, they aim to improve patient compliance and expand access, thus enhancing the potential impact on cancer care—a crucial step toward broader therapeutic accessibility.In an effort to address cost barriers and stimulate domestic production of generics, Mark Cuban has proposed lowering FDA fees. This proposal highlights ongoing discussions around regulatory reforms needed to boost generics manufacturing in the United States. Such initiatives align with broader industry goals of increasing access to affordable medications.Despite these advancements, industry insiders have expressed concerns about "unprecedented turmoil" within the FDA. These challenges underscore the critical role of stable leadership in maintaining public trust and ensuring effective regulation amidst rapid scientific progress.Obesity treatments are gaining significant attention as companies like Wave Life Sciences and Structure Therapeutics report promising data, capturing increased investor interest. This trend underscores a growing focus on innovative pharmacological approaches to address obesity—a complex, multifactorial condition that affects millions globally.The strategic landscape of cancer diagnostics is also evolving, as evidenced by Natera's acquisition of Foresight Diagnostics. This deal underscores ongoing industry consolidation efforts aimed at enhancing technological capabilities and expanding market presence—a testament to the critical role diagnostics play in comprehensive cancer care strategies.As we observe these developments, it's clear that scientific innovation coupled with strategic regulatory maneuvers is shaping the future of healthcare. These advancements offer profound implications for patient care, providing new hope through advanced therapies while highlighting the importance of effective regulation and strategic partnerships.Precision medicine continues to extend beyond oncology into fields like cardiometabolic and neSupport the show

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Sean Ainsworth, CEO and Chairman at Immusoft, talks about transitioning from the research bench to entrepreneurship, his M&A experiences as a biotech founder, and why engineered B cell therapies offer a better, more patient-friendly administration for lysosomal storage diseases currently treated with enzyme replacement therapies. Sean also discusses FDA pathways, incentives, and agency engagement, and offers thoughts on the regulatory outlook for cell and gene therapies.     Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

This episode dives into the fascinating intersection of biotech, AI, and automation with Mr. Guru Singh, CEO/Founder of Scispot and Y Combinator alumnus. Learn how a data-driven, autonomous lab future is taking shape.Could labs run by AI agents and robots cure cancer and revolutionize manufacturing within a decade, and what role does critical thinking play in the AI era?✅ The Digital Brain of the Lab: Discover how Scispot is building an operating layer to connect siloed data, turning life science labs into autonomous, data-driven research centers.

Juan Moreno thinks public markets look more overheated than private markets. Investors are “looking at a lot of the capex spending” and wondering what the ROI is, he argues. He discusses how to find winners in the tech environment, along with AI opportunities for healthcare and biotech. ======== Schwab Network ========Empowering every investor and trader, every market day.Options involve risks and are not suitable for all investors. Before trading, read the Options Disclosure Document. http://bit.ly/2v9tH6DSubscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/About Schwab Network - https://schwabnetwork.com/about

My guest this week is Ian Keldoulis, co-author of Unblinded: The Startup That Launched a Revolution in Saving Sight. He wrote the book with Dr. David Guyer, chronicling the founding of Eyetech Pharmaceuticals in 2000. They developed Macugen, the first effective treatment for age-related macular degeneration (AMD), a disease that once blinded millions in their later years.Unblinded on AmazonUnblinded on Barnes & NobleUnblinded on the publisher's storefrontBlog post available at: https://www.sharesforbeginners.com/blog/ian-keldoulisWatch on YouTube right here.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we dive into a series of pivotal events shaping the landscape of drug development and patient care. The interplay between scientific advancements, regulatory shifts, and strategic partnerships is setting the stage for significant transformations within the industry.A highlight of recent developments is the legal challenge faced by Merck & Co. regarding its new subcutaneous version of Keytruda. This immunotherapy, already a breakthrough in cancer treatment, has encountered a hurdle in Germany where Halozyme, known for its drug-delivery technologies, has secured a preliminary injunction. This move by a German court halts Merck's activities related to Keytruda SC in Germany and underscores the intricate web of intellectual property rights in drug launches across international markets. The outcome of this case could establish crucial precedents for future commercialization efforts involving advanced drug delivery technologies.Meanwhile, there's promising news from Bristol Myers Squibb as their CAR-T therapy, Breyanzi, receives its fifth FDA approval, this time for marginal zone lymphoma. This approval is particularly noteworthy as it marks Breyanzi as the first CAR-T treatment sanctioned for this specific indication and extends its use across five different types of blood cancers. CAR-T therapies continue to represent a frontier in cancer treatment by leveraging the body's immune system to combat malignancies more effectively. This success story from Bristol Myers Squibb highlights the expanding potential of CAR-T therapies in tackling various hematological cancers, offering renewed hope for patients with limited treatment avenues.On the regulatory front, the FDA's proposal to consider single-trial approvals for certain drugs has sparked considerable debate. While some industry voices express concerns about potential compromises to safety and efficacy standards, others see it as an opportunity to invigorate research and development investments by reducing both time and costs associated with bringing new therapies to market. This shift could indeed accelerate innovation but will necessitate a careful balance to uphold rigorous safety standards.In parallel regulatory news, Daiichi Sankyo has received an "untitled letter" from the FDA over its patient ambassador video for Turalio, indicating ongoing challenges in navigating drug promotion guidelines and patient engagement strategies. Such interactions emphasize the complexities pharmaceutical companies face within regulatory frameworks.Shifting focus to corporate strategies, Mark Cuban's Cost Plus Drugs is exploring a partnership with Humana aimed at addressing prescription drug costs for employers. This collaboration seeks to reduce healthcare expenses through innovative pricing models and distribution channels, reflecting a broader industry trend toward cost containment and value-based care delivery.In another development affecting public health policy, the CDC's Advisory Committee on Immunization Practices has postponed its vote on changes to newborn hepatitis B vaccine policies due to ongoing debates and confusion surrounding the topic. This delay highlights the intricate nature of updating long-standing public health policies, especially those impacting vaccination schedules.From an investment perspective, Freenome's decision to go public through a $330 million SPAC deal stands out. Specializing in developing blood tests for early cancer detection using machine learning technologies, Freenome's move aims to secure capital necessary for advancing its diagnostic tools—potentially transforming cancer screening practices by enabling earlier detection and intervention.In clinical trial news, Praxis Precision Medicines reported positive efficacy results from a Phase 2 trialSupport the show

Diese Sonntags-Sonderfolge von „Alles auf Aktien“ ist das große Finale. Heute bekommt ihr eure vier finalen Pitches. Und die haben es in sich. Zuerst stellt sich ein Biotech-Akteur vor, der jedoch kurz vor dem Blockbuster-Moment steht. Dann erlebt ihr einen erstaunlich schlagfertigen CEO, der wehmütig nach Amerika schaut. Ihm folgt der Macher, dessen großer Traum in einer Gartenlaube begann – und der seine Technologie heute groß rausbringt. Und zum Schluss gibt es Rüstung und es geht um eine Aktie, die aus gutem Grund abgestürzt ist – doch nun eine neue Story birgt. Heute pitchen bei uns, für Euch …  Newron, Eckert&Ziegler, Pyrum und und Steyr Motors.  Die aktuelle "Alles auf Aktien"-Umfrage findet Ihr unter: https://www.umfrageonline.com/c/mh9uebwm Wir freuen uns an Feedback über aaa@welt.de. Noch mehr "Alles auf Aktien" findet Ihr bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this episode of Excess Returns, Graeme Forster of Orbis joins us to discuss two major research papers: Six Courageous Questions for 2026 and Sunrise on Venus. We explore how long-running global trends may be reversing, what that means for U.S. dominance, the future of international and emerging markets, the risks and opportunities created by AI and massive CapEx spending, the dollar's shifting role, and how investors should think about valuation, humility, and navigating a world where the economic “water” is changing. This conversation is packed with global macro insight, long-term investing lessons, and practical frameworks for building more resilient portfolios. Topics Covered:• Why long-term market “water” becomes invisible to investors• Self-reinforcing global cycles and how China's WTO entry reshaped the world• Signs the 25-year U.S. outperformance cycle may be breaking• How tariffs, political shifts, and corporate reforms change the global landscape• Why international and emerging markets may now offer better expected returns• Why U.S. large caps are not the entire story of American exceptionalism• How to think about valuation, margins, and discounted cash flow models across markets• The AI boom, bubbles, capital cycles, and asymmetric outcomes• How AI CapEx constraints influence winners and losers• The shifting role of the U.S. dollar and why market shocks may behave differently• Maslow's hierarchy, needs vs. wants, and the return of state-driven capital investment• Deglobalization, reshoring, and the national-security lens for investing• How to evaluate China and Taiwan inside emerging markets• Why humility is an investor's greatest edgeTimestamps:00:00 Introduction01:02 Why Orbis wrote Six Courageous Questions for 202603:44 The David Foster Wallace “water” analogy and investing06:12 How a 25-year self-reinforcing cycle powered U.S. outperformance10:12 Signs the cycle may be breaking12:00 Corporate reform and opportunity in Asia13:55 Why active share, benchmarking, and incentives distort investor behavior17:31 Decomposing S&P 500 returns: margins, valuations, fundamentals20:20 Expected returns inside and outside the U.S.22:34 Why international stocks offer richer opportunity sets24:25 Currency implications and weakening dollar dynamics26:18 American exceptionalism beyond the top 10 mega caps28:49 Where Orbis is finding value today30:25 Biotech, healthcare, and post-COVID dislocation31:05 How Orbis thinks about valuation in an intangible-heavy world32:09 Is AI a bubble or the beginning of something bigger?34:30 Game theory of AI CapEx and right-tail outcomes36:00 CapEx cycles, history, and who benefits38:00 Indirect AI beneficiaries and the SK Square example40:35 Maslow's hierarchy and the shift from wants to needs42:32 Deglobalization, national security, and domestic reinvestment44:00 Capital returning to home markets and strategic industries46:00 Can anything reverse these structural trends?48:00 Balancing bottom-up investing with macro awareness49:45 The deeper risk in emerging markets: owning vs. avoiding51:00 Valuation still matters for long-term returns52:29 Corporate behavior, dividends, and re-rating cycles53:52 How Orbis views China vs. bottom-up opportunity55:34 Why great investors must be right 90–95% of the time in decision quality58:00 One lesson Graeme would teach the average investor

Welcome to this episode of The Edge of Show, where we dive deep into the world of Web3, blockchain, and the future of finance! Join us with our special guest BrendanSedo from Core as they explore hot topics including:The impact of large public companies like Strategy Inc. holding massive Bitcoin treasuries and the risks involved.Texas became the first U.S. state to officially buy Bitcoin for its treasury, signaling a shift in government sentiment towards crypto.The evolution of neobanks into self-custodial financial apps, blurring the lines between traditional banking and decentralized finance.An in-depth look at CoreDAO, a high-performance Layer 1 blockchain designed to extend Bitcoin into DeFi and DApps, including exciting updates on their new liquid staking token.Whether you're a crypto enthusiast, a fintech professional, or just curious about the future of money, this episode is packed with insights and analysis that you won't want to miss!Tune in now and join the conversation!

Dr. Ying Huang, CEO of Legend Biotech (LEGN), explains the work his company does on white blood cell cancer. They grew revenue from the drug 84% last quarter to over $500 million, and expect to turn a profit in 2026. He discusses their partnership with Johnson & Johnson (JNJ), international expansion, and the research they're conducting.======== Schwab Network ========Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – https://twitter.com/schwabnetworkFollow us on Facebook – https://www.facebook.com/schwabnetworkFollow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

Biotech networking doesn't have to feel random. In this video, I'll walk you through a 28-day biotech networking challenge you can actually stick to.Perfect for biotech job seekers who want a clear, daily plan to grow their biotech career network in December and beyond.Here's what you'll learn:-Why December is secretly a powerful month for biotech networking-How to track your LinkedIn analytics so you know what's really working-A simple system to map out target companies, teams, and hiring managers-How to send authentic, personalised connection requests that don't feel salesy-Easy ways to nurture existing connections without being pushy or awkward-How to create and share quick LinkedIn content that expands your reach-Strategies to comment on posts so you stand out (without sounding generic)-Exactly how to ask for coffee chats that open doors in biotech-How to keep each step under 30 minutes a day so you can stay consistent-Turning this 28-day challenge into a repeatable, year-round networking habitThis 28-day biotech networking challenge is the same one we're running inside my Biotech Career Coach Skool community. You can join in with us or follow along solo – it's designed so your “Day 1” can start whenever you're ready.By the end of the challenge, you'll have:-A stronger biotech network-More visibility to recruiters and hiring managers-Clearer data on what's working in your job search-Real momentum heading into interview season

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, the landscape of the pharmaceutical and biotech industries is marked by groundbreaking scientific advancements, regulatory shifts, and strategic collaborations that promise to reshape patient care and drug development significantly.A controversy has emerged in the wake of proposed changes to U.S. vaccine regulations by Dr. Vinay Prasad, a senior FDA official. This proposal has sparked considerable opposition from 12 former FDA commissioners who argue that these regulatory overhauls could potentially undermine public trust in vaccines. Former leaders from both the CDC and FDA have expressed concerns over these proposed vaccine policy changes during an ACIP meeting, discussions that could influence future public health strategies and vaccine trust. At a time when vaccine confidence is crucial, maintaining the integrity of regulatory processes is vital to public health efforts.Leadership changes are also afoot within the FDA, as Dr. Tracy Beth Hoeg steps into the role of acting director for the Center for Drug Evaluation and Research. Her appointment signals a shift towards leaders with direct experience in public health crises. This comes amidst further internal restructuring at the FDA, including the transfer of Theresa Michele, long-standing director of the Office of Nonprescription Drugs, indicating dynamic changes within the agency.In the realm of oncology, Eli Lilly's progress with its Bruton's tyrosine kinase inhibitor, Jaypirca, is noteworthy. The drug's expanded label now includes earlier treatment stages for chronic lymphocytic leukemia and small lymphocytic lymphoma. This expansion underscores the therapeutic potential of non-covalent BTK inhibitors and may significantly improve patient outcomes by offering earlier intervention options.Geopolitical challenges are impacting the industry as WuXi AppTec, a major China-based biopharmaceutical contractor, faces scrutiny from the Pentagon amid concerns about its potential ties with the Chinese military. This development highlights the complex interplay between global security concerns and international biotech collaborations. The intersection of global security concerns continues to impact biopharmaceutical supply chains as WuXi AppTec faces increased scrutiny from U.S. authorities.On the manufacturing front, Quvara Medical's emergence as a new contract development and manufacturing organization following Buckland Group's acquisition of a Becton Dickinson facility in the UK reflects industry trends toward consolidating manufacturing capabilities to meet growing biopharmaceutical demand efficiently.AstraZeneca is enhancing its pipeline through a renewed partnership with Neurimmune for an amyloidosis asset. This collaboration, potentially worth up to $780 million, highlights AstraZeneca's strategic focus on rare diseases and underscores their commitment to expanding their therapeutic portfolio through successful alliances.Regulatory updates from the FDA propose reductions in user fees for early-stage clinical trials conducted domestically while considering additional fees for overseas developments. This initiative aims to incentivize research activities within the U.S., potentially accelerating drug discovery timelines and fostering domestic innovation.In surgical technology advancements, Medtronic's Hugo surgical robot has secured FDA clearance for procedures involving prostate, kidney, and bladder removal. This marks a significant advancement in robotic-assisted surgeries and could enhance patient outcomes across approximately 230,000 surgeries annually in the U.S.As we explore more about financial maneuvers within this sector, Royalty Pharma's $275 million financing deal for Denali Therapeutics' Hunter syndrome drug reflects confidence in Denali's pipeline pendinSupport the show

Episode 5 of Standard Deviation with Oliver Bogler on the Out of Patients podcast feed pulls you straight into the story of Dr Ethan Moitra, a psychologist who fights for LGBTQ mental health while the system throws every obstacle it can find at him.Ethan built a study that tracked how COVID 19 tore through an already vulnerable community. He secured an NIH grant. He built a team. He reached 180 participants. Then he opened an email on a Saturday and learned that Washington had erased his work with one sentence about taxpayer priorities. The funding vanished. The timeline collapsed. His team scattered. Participants who trusted him sat in limbo.A federal court eventually forced the government to reinstate the grant, but the damage stayed baked into the process. Ethan had to push through months of paperwork while his university kept the original deadline as if the shutdown had not happened. The system handed him a win that felt like a warning.I brought Ethan on because his story shows how politics reaches into science and punishes the people who serve communities already carrying too much trauma. His honesty lands hard because he names the fear now spreading across academia and how young scientists question whether they can afford to care about the wrong population.You will hear what this ordeal did to him, what it cost his team, and why he refuses to walk away.RELATED LINKSFaculty PageNIH Grant DetailsScientific PresentationBoston Globe CoverageFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Welcome to this episode of The Edge of Show, your gateway to the Web3 revolution! In this episode we sit down with Dr. Mohamed Omer Ali, the founder of EazyBot, and Winston Thomas, the Global Sales Director of EazyBot. Together, they explore the transformative world of cryptocurrency, automation, and trading strategies.Episode Highlights:Discover the inspiration behind EazyBot and how it aims to empower users in the crypto space.Learn about Dr. Ali's journey from engineering to crypto and the pivotal moments that led to the creation of EazyBot.Understand the importance of safety in trading and how EazyBot ensures users maintain custody of their assets.Hear insights on the current state of the crypto market, including Bitcoin's volatility and the significance of diversification in trading strategies.Get a sneak peek into upcoming features and partnerships for EazyBot, including new exchanges and a mobile app.Whether you're a seasoned trader or just starting your crypto journey, this episode is packed with valuable insights and practical advice. Join us as we navigate the future of finance and technology!Support us through our Sponsors! ☕

In this episode of Data in Biotech, Ross Katz chats with Wesley Tatum, Principal Engineer at Serán BioScience, about the intricacies of formulating low-solubility drug products. They explore the science behind amorphous solid dispersions, how data informs formulation choices, and why balancing performance, manufacturability, and stability is critical in modern drug development. What you'll learn in this episode: >> How amorphous solid dispersions improve solubility and stability in drug products >> Why formulation decisions hinge on early data collection and modeling >> The role of data infrastructure in formulation R&D and knowledge transfer >> How Serán BioScience collaborates closely with clients to solve complex drug development challenges >> Where AI and automation are (and aren't yet) transforming pharmaceutical formulation Meet our guest Wesley Tatum is a Materials Science PhD researcher working at the crossroads of materials innovation, data science, and machine learning. His work focuses on organic materials and polymer dispersions, and he's especially passionate about how modern computational tools can transform the way we characterize and understand new materials. Wesley is well versed in PyTorch, Scikit-Learn, and a range of open-source scientific computing libraries, and he brings deep experience in chemical analysis, microscopy, and image analysis.  About The Host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with Our Guest: Sponsor: CorrDyn, a data consultancyConnect with Wesley Tatum on LinkedIn  Connect with Us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.

What does the future of biotech look like when curiosity, not competition, leads the way? In this episode, host Elaine Hamm, PhD, talks with Aziz Abadsafian, MBA, Technology Scout at Nissan Chemical America. Together, they dive into the “edges” of science — the more speculative world of embryology, longevity, and what Aziz calls the true frontier of biotech. Along the way, they explore how curiosity, relationship-building, and “night science” conversations can unlock unexpected opportunities in your career and in the industry. In this episode, you'll learn: Why the biggest biotech opportunities lie at the extremes – in aging, fertility, longevity, and neurodegeneration. How curiosity and genuine relationships lead to better collaborations than transactional networking ever could. Practical advice for scientists and students on finding your path, staying inspired, and building a career that aligns with what you're good at AND what you love. Tune in for a thoughtful, funny, and wide-ranging conversation about discovery, imagination, and why the future of biotech will always belong to the relentlessly curious. Links: Connect with Aziz Abadsafian, MBA, and check out Nissan Chemical America. Connect with Elaine Hamm, PhD, and learn about Tulane Medicine Business Development and the School of Medicine. Check out our previous episode with Cain McClary. Connect with Ian McLachlan, BIO from the BAYOU producer. Check out BIO on the BAYOU. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of significant shifts and advancements shaping these dynamic industries.Let's begin with Imvax, a biotechnology company that's making waves with its brain cancer cell therapy. Despite not hitting the primary endpoint in their Phase 2b trial, Imvax has taken the bold step of submitting their therapy to the FDA. This decision is rooted in the promising overall survival data observed during the trial. It highlights a growing trend where survival metrics are becoming critical indicators of a therapy's potential value. The company's pursuit of regulatory approval underscores an ongoing commitment within the industry to address challenging conditions like brain cancer with innovative treatment options.Meanwhile, Janux Therapeutics is facing its own set of challenges with its T-cell engager technology. Recent setbacks have led to a notable dip in stock value, yet analysts remain optimistic. The technology, despite current hurdles, holds promise for delivering best-in-class treatments. This situation reflects the inherent volatility and high stakes in biotech investments, where initial enthusiasm must be backed by consistent and robust clinical data to sustain market confidence.Tiziana Life Sciences is making strategic moves by spinning out its IL-6 drug into a separate entity. This decision comes amid heightened interest from major pharmaceutical players in the IL-6 pathway, known for its role in immune response modulation. The spinout strategy is part of a broader industry trend where companies are reorganizing their portfolios to focus on high-potential candidates that align with market demands and emerging scientific interests.Regulatory landscapes are also evolving with significant implications. The FDA's release of draft guidance aims to reduce primate testing for certain monoclonal antibodies, reflecting a broader ethical shift toward minimizing animal testing through alternative methods. This move aligns with global trends favoring more humane research methodologies and will likely influence how companies approach preclinical testing phases.In Europe, the EU's collaboration with Angelini Industries is injecting €150 million into health startups across the continent. This investment seeks to accelerate growth in digital health technologies, which are increasingly integral to modern healthcare solutions. Such funding initiatives are crucial for fostering innovation within Europe's biotech and medtech sectors.Across the Atlantic, legislative efforts in the United States are gaining momentum. The revival of the FDA's rare pediatric disease priority review voucher program highlights ongoing support for pediatric drug development. These vouchers incentivize treatments for rare diseases affecting children, addressing an area of unmet medical need that requires specific regulatory attention. This initiative has received unanimous support from Congress through the "Give Kids a Chance Act," underscoring a renewed commitment to treatments for rare pediatric diseases—a critical area where unmet medical needs persist due to limited commercial incentives.The FDA is also embracing cutting-edge technologies like agentic artificial intelligence (AI) to streamline its operations. AI tools have the potential to enhance decision-making efficiency and support more personalized medicine approaches, reflecting a commitment to integrating technology into regulatory processes.On the public health front, changes are underway as the CDC's Advisory Committee on Immunization Practices prepares to discuss updates on hepatitis B vaccines and childhood immunization schedules under new leadership. Such discussions are vital as they could shape future public health policies and vaccination strategies amid evolving data andSupport the show

Chelsea J. Smith walks into a studio and suddenly I feel like a smurf. She's six-foot-three of sharp humor, dancer's poise, and radioactive charm. A working actor and thyroid cancer survivor, Chelsea is the kind of guest who laughs while dropping truth bombs about what it means to be told you're “lucky” to have the “good cancer.” We talk about turning trauma into art, how Shakespeare saved her sanity during the pandemic, and why bartending might be the best acting class money can't buy. She drops the polite bullshit, dismantles survivor guilt with punchline precision, and reminds every listener that grace and rage can live in the same body. If you've ever been told to “walk it off” while your body betrayed you, this one hits close.RELATED LINKS• Chelsea J. Smith Website• Chelsea on Instagram• Chelsea on Backstage• Chelsea on YouTube• Cancer Hope Network• Artichokes and Grace – Book by Chelsea's motherFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

For this episode I am joined by Megan and JC Leston, two parents who are fighting for their son Liam. The oldest of their five children, Liam was born with the rare Cri du Chat or 5p- syndrome. Through years of perseverance, they have created the Cri du Chat Foundation and started a movement to find a cure not only for Liam, but for all families affected by this genetic disease.Listen now to hear their story, and find out more about their work and how you can help at www.criduchatresearch.org.

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Dan Schmitt, President and CEO at Actuate Therapeutics, talks about building a company around elraglusib, a GSK-3β inhibitor for cancer. Dan describes his fast-fail approach to early product testing and development, using basket trials to evaluate chemotherapy combinations, and choosing pancreatic cancer as a lead program. He also talks about surviving an IPO during a brutal funding cycle for biotech, building lean teams and efficient operations, and potentially onshoring API in response to changing U.S. policy. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

In this episode, Darin sits down with BioHarvest CEO Ilan Sobel, a leader who is redefining the future of plant compounds, human performance, and scalable biotech. Ilan shares the extraordinary origin story of BioHarvest's technology, how a single scientific breakthrough is disrupting global supply chains, and why "democratizing the power of the plant kingdom" has become his life mission. From hydration to longevity molecules to the French Paradox, Ilan reveals how his company is transforming ancient wisdom into modern, clinically validated solutions that can reach the masses.     What You'll Learn 00:00:00 Welcome and Introduction 00:00:32 Sponsor: Thera Sage 00:02:10 Introducing Ilan Sobel (Bio Harvest Sciences) 00:03:37 Electrolyte Solution Powered by Circulation 00:04:37 Vinia's Baseline: Sea Salt, Coconut Water, Marine Magnesium 00:05:36 The Uniqueness of Pi-Seed Resveratrol 00:06:50 Solubility and Bioavailability: Lasting 12 Hours 00:08:48 Overview of Botanical Synthesis Technology and Cell Growth 00:13:58 Vinia's Potency: 1,000 Red Grapes in a Capsule 00:15:31 Why Blood Flow is Critical for Longevity 00:17:23 Increased Blood Flow to the Brain and Mental Alertness 00:19:00 Sponsor: Our Place Cookware 00:21:35 The Abuse of Nature and the Need for Preservation 00:24:15 Overcoming Pharma's Barriers: Consistency, Low Levels, and Patents 00:28:32 Vinia as a Validation of the Technology's Power 00:30:02 Scaling Production: 137 Bioreactors 00:32:21 Scaling Comparison: Manhattan Island's Worth of Resveratrol 00:34:26 Clinical Substantiation and Solubility 00:35:14 The Mechanism: Increasing Nitric Oxide and Reducing ET-1 00:38:33 The "Vinia Difference" - When Consumers Feel the Benefits 00:40:05 Unseen Benefits: Reducing Oxidative Damage 00:41:16 Low Churn Rate and Science-Backed Commitment 00:42:52 Sponsor: Manna Vitality 00:44:46 Commitment to Mission and Customer Reviews as Fuel 00:48:01 Support for First Responders and Veterans 00:51:32 Ilan's Journey to CEO and Unlocking the Gold Mine 00:55:37 The Plan to Build a Second 100-Ton Facility 00:57:12 Democratization and Scaling: Software Economics in Biotech 01:00:21 The French Paradox and Red Wine Connection 01:01:33 Next in DTC: Olive Cells and Forbascoside for Liver Health 01:05:36 New Partnership: Creating a Super Saffron for Cognitive Health 01:13:02 Partnership with Tate & Lyle for Non-Nutritive Sweeteners 01:16:11 The Movement of Change and Legacy for Future Generations 01:18:52 Introducing the Vinia Blood Flow Hydration Stick Packs     Thank You to Our Sponsors Therasage: Go to www.therasage.com and use code DARIN at checkout for 15% off Our Place: Toxic-free, durable cookware that supports healthy cooking. Go to their website at fromourplace.com/darin and get 35% off sitewide in their largest sale of the year. Manna Vitality: Go to mannavitality.com/ and use code DARIN12 for 12% off your order.     Join the SuperLife Community Get Darin's deeper wellness breakdowns — beyond social media restrictions: Weekly voice notes Ingredient deep dives Wellness challenges Energy + consciousness tools Community accountability Extended episodes Join for $7.49/month → https://patreon.com/darinolien     Find More from Ilan Sobel Website: bioharvest.com Instagram: @ilansobel Red Grape Cell Product: vinia.com     Find More from Darin Olien: Instagram: @darinolien Podcast: SuperLife Podcast Website: superlife.com Book: Fatal Conveniences     Key Takeaway "Democratizing the plant kingdom isn't just a business strategy — it's a responsibility. If science gives us the ability to help millions of people feel better, perform better, and live longer, then we have an obligation to scale it in a way the whole world can access."

Join us for this exciting episode of Hot Topics on the Edge of Show as host Josh Krieger dives deep into the latest developments in the world of cryptocurrency and blockchain technology. In this episode, we are joined by Jonathan Baha'i from TOTO and Michael Ros from Sleap.io, both of whom were key sponsors at the recent Future of Money, Governance, and Law Summit in Washington, D.C.Episode Highlights: The rise of altcoin ETFs and their potential to reshape the crypto landscape, especially in light of Bitcoin's recent struggles.Polymarket receiving regulatory approval from the CFTC, paving the way for a new era of prediction markets.How TOTO is leveraging blockchain to redefine civic engagement and governance.Impact of the upcoming FIFA World Cup on travel trends and how Sleep.io is revolutionizing travel bookings with crypto.Whether you're a crypto enthusiast, a travel lover, or just curious about the future of governance, this episode is packed with valuable insights and thought-provoking discussions.Support us through our Sponsors! ☕

Join us for an insightful episode of The Edge of Show as we dive deep into the world of blockchain technology with Fahmi Syed, the president of Midnight Foundation. Recorded live at Creative Blockchain Week, Fahmi shares his journey from traditional finance to the innovative realm of blockchain, discussing the importance of privacy, governance, and the future of digital systems.In this episode, we explore:The role of token holders and DAOs in holding foundations accountable.How Midnight is leveraging zero-knowledge technology to create a permissionless public blockchain that prioritizes privacy.Real-world use cases in healthcare, finance, and GovTech that demonstrate the potential of Midnight's solutions.The evolving regulatory landscape and its impact on blockchain adoption.Ambitious goals for the future, including partnerships with major corporations and governments.Whether you're a blockchain enthusiast, a developer, or just curious about the future of digital systems, this episode is packed with valuable insights and forward-thinking ideas.Don't forget to like, subscribe, and hit the notification bell to stay updated on our latest episodes!Support us through our Sponsors! ☕

How can you write science-based fiction without info-dumping your research? How can you use AI tools in a creative way, while still focusing on a human-first approach? Why is adapting to the fast pace of change so difficult and how can we make the most of this time? Jamie Metzl talks about Superconvergence and more. In the intro, How to avoid author scams [Written Word Media]; Spotify vs Audible audiobook strategy [The New Publishing Standard]; Thoughts on Author Nation and why constraints are important in your author life [Self-Publishing with ALLi]; Alchemical History And Beautiful Architecture: Prague with Lisa M Lilly on my Books and Travel Podcast. Today's show is sponsored by Draft2Digital, self-publishing with support, where you can get free formatting, free distribution to multiple stores, and a host of other benefits. Just go to www.draft2digital.com to get started. This show is also supported by my Patrons. Join my Community at Patreon.com/thecreativepenn Jamie Metzl is a technology futurist, professional speaker, entrepreneur, and the author of sci-fi thrillers and futurist nonfiction books, including the revised and updated edition of Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. You can listen above or on your favorite podcast app or read the notes and links below. Here are the highlights and the full transcript is below. Show Notes How personal history shaped Jamie's fiction writing Writing science-based fiction without info-dumping The super convergence of three revolutions (genetics, biotech, AI) and why we need to understand them holistically Using fiction to explore the human side of genetic engineering, life extension, and robotics Collaborating with GPT-5 as a named co-author How to be a first-rate human rather than a second-rate machine You can find Jamie at JamieMetzl.com. Transcript of interview with Jamie Metzl Jo: Jamie Metzl is a technology futurist, professional speaker, entrepreneur, and the author of sci-fi thrillers and futurist nonfiction books, including the revised and updated edition of Superconvergence: How the Genetics, Biotech, and AI Revolutions Will Transform Our Lives, Work, and World. So welcome, Jamie. Jamie: Thank you so much, Jo. Very happy to be here with you. Jo: There is so much we could talk about, but let's start with you telling us a bit more about you and how you got into writing. From History PhD to First Novel Jamie: Well, I think like a lot of writers, I didn't know I was a writer. I was just a kid who loved writing. Actually, just last week I was going through a bunch of boxes from my parents' house and I found my autobiography, which I wrote when I was nine years old. So I've been writing my whole life and loving it. It was always something that was very important to me. When I finished my DPhil, my PhD at Oxford, and my dissertation came out, it just got scooped up by Macmillan in like two minutes. And I thought, “God, that was easy.” That got me started thinking about writing books. I wanted to write a novel based on the same historical period – my PhD was in Southeast Asian history – and I wanted to write a historical novel set in the same period as my dissertation, because I felt like the dissertation had missed the human element of the story I was telling, which was related to the Cambodian genocide and its aftermath. So I wrote what became my first novel, and I thought, “Wow, now I'm a writer.” I thought, “All right, I've already published one book. I'm gonna get this other book out into the world.” And then I ran into the brick wall of: it's really hard to be a writer. It's almost easier to write something than to get it published. I had to learn a ton, and it took nine years from when I started writing that first novel, The Depths of the Sea, to when it finally came out. But it was such a positive experience, especially to have something so personal to me as that story. I'd lived in Cambodia for two years, I'd worked on the Thai-Cambodian border, and I'm the child of a Holocaust survivor. So there was a whole lot that was very emotional for me. That set a pattern for the rest of my life as a writer, at least where, in my nonfiction books, I'm thinking about whatever the issues are that are most important to me. Whether it was that historical book, which was my first book, or Hacking Darwin on the future of human genetic engineering, which was my last book, or Superconvergence, which, as you mentioned in the intro, is my current book. But in every one of those stories, the human element is so deep and so profound. You can get at some of that in nonfiction, but I've also loved exploring those issues in deeper ways in my fiction. So in my more recent novels, Genesis Code and Eternal Sonata, I've looked at the human side of the story of genetic engineering and human life extension. And now my agent has just submitted my new novel, Virtuoso, about the intersection of AI, robotics, and classical music. With all of this, who knows what's the real difference between fiction and nonfiction? We're all humans trying to figure things out on many different levels. Shifting from History to Future Tech Jo: I knew that you were a polymath, someone who's interested in so many things, but the music angle with robotics and AI is fascinating. I do just want to ask you, because I was also at Oxford – what college were you at? Jamie: I was in St. Antony's. Jo: I was at Mansfield, so we were in that slightly smaller, less famous college group, if people don't know. Jamie: You know, but we're small but proud. Jo: Exactly. That's fantastic. You mentioned that you were on the historical side of things at the beginning and now you've moved into technology and also science, because this book Superconvergence has a lot of science. So how did you go from history and the past into science and the future? Biology and Seeing the Future Coming Jamie: It's a great question. I'll start at the end and then back up. A few years ago I was speaking at Lawrence Livermore National Laboratory, which is one of the big scientific labs here in the United States. I was a guest of the director and I was speaking to their 300 top scientists. I said to them, “I'm here to speak with you about the future of biology at the invitation of your director, and I'm really excited. But if you hear something wrong, please raise your hand and let me know, because I'm entirely self-taught. The last biology course I took was in 11th grade of high school in Kansas City.” Of course I wouldn't say that if I didn't have a lot of confidence in my process. But in many ways I'm self-taught in the sciences. As you know, Jo, and as all of your listeners know, the foundation of everything is curiosity and then a disciplined process for learning. Even our greatest super-specialists in the world now – whatever their background – the world is changing so fast that if anyone says, “Oh, I have a PhD in physics/chemistry/biology from 30 years ago,” the exact topic they learned 30 years ago is less significant than their process for continuous learning. More specifically, in the 1990s I was working on the National Security Council for President Clinton, which is the president's foreign policy staff. My then boss and now close friend, Richard Clarke – who became famous as the guy who had tragically predicted 9/11 – used to say that the key to efficacy in Washington and in life is to try to solve problems that other people can't see. For me, almost 30 years ago, I felt to my bones that this intersection of what we now call AI and the nascent genetics revolution and the nascent biotechnology revolution was going to have profound implications for humanity. So I just started obsessively educating myself. When I was ready, I started writing obscure national security articles. Those got a decent amount of attention, so I was invited to testify before the United States Congress. I was speaking out a lot, saying, “Hey, this is a really important story. A lot of people are missing it. Here are the things we should be thinking about for the future.” I wasn't getting the kind of traction that I wanted. I mentioned before that my first book had been this dry Oxford PhD dissertation, and that had led to my first novel. So I thought, why don't I try the same approach again – writing novels to tell this story about the genetics, biotech, and what later became known popularly as the AI revolution? That led to my two near-term sci-fi novels, Genesis Code and Eternal Sonata. On my book tours for those novels, when I explained the underlying science to people in my way, as someone who taught myself, I could see in their eyes that they were recognizing not just that something big was happening, but that they could understand it and feel like they were part of that story. That's what led me to write Hacking Darwin, as I mentioned. That book really unlocked a lot of things. I had essentially predicted the CRISPR babies that were born in China before it happened – down to the specific gene I thought would be targeted, which in fact was the case. After that book was published, Dr. Tedros, the Director-General of the World Health Organization, invited me to join the WHO Expert Advisory Committee on Human Genome Editing, which I did. It was a really great experience and got me thinking a lot about the upside of this revolution and the downside. The Birth of Superconvergence Jamie: I get a lot of wonderful invitations to speak, and I have two basic rules for speaking: Never use notes. Never ever. Never stand behind a podium. Never ever. Because of that, when I speak, my talks tend to migrate. I'd be speaking with people about the genetics revolution as it applied to humans, and I'd say, “Well, this is just a little piece of a much bigger story.” The bigger story is that after nearly four billion years of life on Earth, our one species has the increasing ability to engineer novel intelligence and re-engineer life. The big question for us, and frankly for the world, is whether we're going to be able to use that almost godlike superpower wisely. As that idea got bigger and bigger, it became this inevitable force. You write so many books, Jo, that I think it's second nature for you. Every time I finish a book, I think, “Wow, that was really hard. I'm never doing that again.” And then the books creep up on you. They call to you. At some point you say, “All right, now I'm going to do it.” So that was my current book, Superconvergence. Like everything, every journey you take a step, and that step inspires another step and another. That's why writing and living creatively is such a wonderfully exciting thing – there's always more to learn and always great opportunities to push ourselves in new ways. Balancing Deep Research with Good Storytelling Jo: Yeah, absolutely. I love that you've followed your curiosity and then done this disciplined process for learning. I completely understand that. But one of the big issues with people like us who love the research – and having read your Superconvergence, I know how deeply you go into this and how deeply you care that it's correct – is that with fiction, one of the big problems with too much research is the danger of brain-dumping. Readers go to fiction for escapism. They want the interesting side of it, but they want a story first. What are your tips for authors who might feel like, “Where's the line between putting in my research so that it's interesting for readers, but not going too far and turning it into a textbook?” How do you find that balance? Jamie: It's such a great question. I live in New York now, but I used to live in Washington when I was working for the U.S. government, and there were a number of people I served with who later wrote novels. Some of those novels felt like policy memos with a few sex scenes – and that's not what to do. To write something that's informed by science or really by anything, everything needs to be subservient to the story and the characters. The question is: what is the essential piece of information that can convey something that's both important to your story and your character development, and is also an accurate representation of the world as you want it to be? I certainly write novels that are set in the future – although some of them were a future that's now already happened because I wrote them a long time ago. You can make stuff up, but as an author you have to decide what your connection to existing science and existing technology and the existing world is going to be. I come at it from two angles. One: I read a huge number of scientific papers and think, “What does this mean for now, and if you extrapolate into the future, where might that go?” Two: I think about how to condense things. We've all read books where you're humming along because people read fiction for story and emotional connection, and then you hit a bit like: “I sat down in front of the president, and the president said, ‘Tell me what I need to know about the nuclear threat.'” And then it's like: insert memo. That's a deal-killer. It's like all things – how do you have a meaningful relationship with another person? It's not by just telling them your story. Even when you're telling them something about you, you need to be imagining yourself sitting in their shoes, hearing you. These are very different disciplines, fiction and nonfiction. But for the speculative nonfiction I write – “here's where things are now, and here's where the world is heading” – there's a lot of imagination that goes into that too. It feels in many ways like we're living in a sci-fi world because the rate of technological change has been accelerating continuously, certainly for the last 12,000 years since the dawn of agriculture. It's a balance. For me, I feel like I'm a better fiction writer because I write nonfiction, and I'm a better nonfiction writer because I write fiction. When I'm writing nonfiction, I don't want it to be boring either – I want people to feel like there's a story and characters and that they can feel themselves inside that story. Jo: Yeah, definitely. I think having some distance helps as well. If you're really deep into your topics, as you are, you have to leave that manuscript a little bit so you can go back with the eyes of the reader as opposed to your eyes as the expert. Then you can get their experience, which is great. Looking Beyond Author-Focused AI Fears Jo: I want to come to your technical knowledge, because AI is a big thing in the author and creative community, like everywhere else. One of the issues is that creators are focusing on just this tiny part of the impact of AI, and there's a much bigger picture. For example, in 2024, Demis Hassabis from Google DeepMind and his collaborative partner John Jumper won the Nobel Prize for Chemistry with AlphaFold. It feels to me like there's this massive world of what's happening with AI in health, climate, and other areas, and yet we are so focused on a lot of the negative stuff. Maybe you could give us a couple of things about what there is to be excited and optimistic about in terms of AI-powered science? Jamie: Sure. I'm so excited about all of the new opportunities that AI creates. But I also think there's a reason why evolution has preserved this very human feeling of anxiety: because there are real dangers. Anybody who's Pollyanna-ish and says, “Oh, the AI story is inevitably positive,” I'd be distrustful. And anyone who says, “We're absolutely doomed, this is the end of humanity,” I'd also be distrustful. So let me tell you the positives and the negatives, and maybe some thoughts about how we navigate toward the former and away from the latter. AI as the New Electricity Jamie: When people think of AI right now, they're thinking very narrowly about these AI tools and ChatGPT. But we don't think of electricity that way. Nobody says, “I know electricity – electricity is what happens at the power station.” We've internalised the idea that electricity is woven into not just our communication systems or our houses, but into our clothes, our glasses – it's woven into everything and has super-empowered almost everything in our modern lives. That's what AI is. In Superconvergence, the majority of the book is about positive opportunities: In healthcare, moving from generalised healthcare based on population averages to personalised or precision healthcare based on a molecular understanding of each person's individual biology. As we build these massive datasets like the UK Biobank, we can take a next jump toward predictive and preventive healthcare, where we're able to address health issues far earlier in the process, when interventions can be far more benign. I'm really excited about that, not to mention the incredible new kinds of treatments – gene therapies, or pharmaceuticals based on genetics and systems-biology analyses of patients. Then there's agriculture. Over the last hundred years, because of the technologies of the Green Revolution and synthetic fertilisers, we've had an incredible increase in agricultural productivity. That's what's allowed us to quadruple the global population. But if we just continue agriculture as it is, as we get towards ten billion wealthier, more empowered people wanting to eat like we eat, we're going to have to wipe out all the wild spaces on Earth to feed them. These technologies help provide different paths toward increasing agricultural productivity with fewer inputs of land, water, fertiliser, insecticides, and pesticides. That's really positive. I could go on and on about these positives – and I do – but there are very real negatives. I was a member of the WHO Expert Advisory Committee on Human Genome Editing after the first CRISPR babies were very unethically created in China. I'm extremely aware that these same capabilities have potentially incredible upsides and very real downsides. That's the same as every technology in the past, but this is happening so quickly that it's triggering a lot of anxieties. Governance, Responsibility, and Why Everyone Has a Role Jamie: The question now is: how do we optimise the benefits and minimise the harms? The short, unsexy word for that is governance. Governance is not just what governments do; it's what all of us do. That's why I try to write books, both fiction and nonfiction, to bring people into this story. If people “other” this story – if they say, “There's a technology revolution, it has nothing to do with me, I'm going to keep my head down” – I think that's dangerous. The way we're going to handle this as responsibly as possible is if everybody says, “I have some role. Maybe it's small, maybe it's big. The first step is I need to educate myself. Then I need to have conversations with people around me. I need to express my desires, wishes, and thoughts – with political leaders, organisations I'm part of, businesses.” That has to happen at every level. You're in the UK – you know the anti-slavery movement started with a handful of people in Cambridge and grew into a global movement. I really believe in the power of ideas, but ideas don't spread on their own. These are very human networks, and that's why writing, speaking, communicating – probably for every single person listening to this podcast – is so important. Jo: Mm, yeah. Fiction Like AI 2041 and Thinking Through the Issues Jo: Have you read AI 2041 by Kai-Fu Lee and Chen Qiufan? Jamie: No. I heard a bunch of their interviews when the book came out, but I haven't read it. Jo: I think that's another good one because it's fiction – a whole load of short stories. It came out a few years ago now, but the issues they cover in the stories, about different people in different countries – I remember one about deepfakes – make you think more about the topics and help you figure out where you stand. I think that's the issue right now: it's so complex, there are so many things. I'm generally positive about AI, but of course I don't want autonomous drone weapons, you know? The Messy Reality of “Bad” Technologies Jamie: Can I ask you about that? Because this is why it's so complicated. Like you, I think nobody wants autonomous killer drones anywhere in the world. But if you right now were the defence minister of Ukraine, and your children are being kidnapped, your country is being destroyed, you're fighting for your survival, you're getting attacked every night – and you're getting attacked by the Russians, who are investing more and more in autonomous killer robots – you kind of have two choices. You can say, “I'm going to surrender,” or, “I'm going to use what technology I have available to defend myself, and hopefully fight to either victory or some kind of stand-off.” That's what our societies did with nuclear weapons. Maybe not every American recognises that Churchill gave Britain's nuclear secrets to America as a way of greasing the wheels of the Anglo-American alliance during the Second World War – but that was our programme: we couldn't afford to lose that war, and we couldn't afford to let the Nazis get nuclear weapons before we did. So there's the abstract feeling of, “I'm against all war in the abstract. I'm against autonomous killer robots in the abstract.” But if I were the defence minister of Ukraine, I would say, “What will it take for us to build the weapons we can use to defend ourselves?” That's why all this stuff gets so complicated. And frankly, it's why the relationship between fiction and nonfiction is so important. If every novel had a situation where every character said, “Oh, I know exactly the right answer,” and then they just did the right answer and it was obviously right, it wouldn't make for great fiction. We're dealing with really complex humans. We have conflicting impulses. We're not perfect. Maybe there are no perfect answers – but how do we strive toward better rather than worse? That's the question. Jo: Absolutely. I don't want to get too political on things. How AI Is Changing the Writing Life Jo: Let's come back to authors. In terms of the creative process, the writing process, the research process, and the business of being an author – what are some of the ways that you already use AI tools, and some of the ways, given your futurist brain, that you think things are going to change for us? Jamie: Great question. I'll start with a little middle piece. I found you, Jo, through GPT-5. I asked ChatGPT, “I'm coming out with this book and I want to connect with podcasters who are a little different from the ones I've done in the past. I've been a guest on Joe Rogan twice and some of the bigger podcasts. Make me a list of really interesting people I can have great conversations with.” That's how I found you. So this is one reward of that process. Let me say that in the last year I've worked on three books, and I'll explain how my relationship with AI has changed over those books. Cleaning Up Citations (and Getting Burned) Jamie: First is the highly revised paperback edition of Superconvergence. When the hardback came out, I had – I don't normally work with research assistants because I like to dig into everything myself – but the one thing I do use a research assistant for is that I can't be bothered, when I'm writing something, to do the full Chicago-style footnote if I'm already referencing an academic paper. So I'd just put the URL as the footnote and then hire a research assistant and say, “Go to this URL and change it into a Chicago-style citation. That's it.” Unfortunately, my research assistant on the hardback used early-days ChatGPT for that work. He did the whole thing, came back, everything looked perfect. I said, “Wow, amazing job.” It was only later, as I was going through them, that I realised something like 50% of them were invented footnotes. It was very painful to go back and fix, and it took ten times more time. With the paperback edition, I didn't use AI that much, but I did say things like, “Here's all the information – generate a Chicago-style citation.” That was better. I noticed there were a few things where I stopped using the thesaurus function on Microsoft Word because I'd just put the whole paragraph into the AI and say, “Give me ten other options for this one word,” and it would be like a contextual thesaurus. That was pretty good. Talking to a Robot Pianist Character Jamie: Then, for my new novel Virtuoso, I was writing a character who is a futurist robot that plays the piano very beautifully – not just humanly, but almost finding new things in the music we've written and composing music that resonates with us. I described the actions of that robot in the novel, but I didn't describe the inner workings of the robot's mind. In thinking about that character, I realised I was the first science-fiction writer in history who could interrogate a machine about what it was “thinking” in a particular context. I had the most beautiful conversations with ChatGPT, where I would give scenarios and ask, “What are you thinking? What are you feeling in this context?” It was all background for that character, but it was truly profound. Co-Authoring The AI Ten Commandments with GPT-5 Jamie: Third, I have another book coming out in May in the United States. I gave a talk this summer at the Chautauqua Institution in upstate New York about AI and spirituality. I talked about the history of our human relationship with our technology, about how all our religious and spiritual traditions have deep technological underpinnings – certainly our Abrahamic religions are deeply connected to farming, and Protestantism to the printing press. Then I had a section about the role of AI in generating moral codes that would resonate with humans. Everybody went nuts for this talk, and I thought, “I think I'm going to write a book.” I decided to write it differently, with GPT-5 as my named co-author. The first thing I did was outline the entire book based on the talk, which I'd already spent a huge amount of time thinking about and organising. Then I did a full outline of the arguments and structures. Then I trained GPT-5 on my writing style. The way I did it – which I fully describe in the introduction to the book – was that I'd handle all the framing: the full introduction, the argument, the structure. But if there was a section where, for a few paragraphs, I was summarising a huge field of data, even something I knew well, I'd give GPT-5 the intro sentence and say, “In my writing style, prepare four paragraphs on this.” For example, I might write: “AI has the potential to see us humans like we humans see ant colonies.” Then I'd say, “Give me four paragraphs on the relationship between the individual and the collective in ant colonies.” I could have written those four paragraphs myself, but it would've taken a month to read the life's work of E.O. Wilson and then write them. GPT-5 wrote them in seconds or minutes, in its thinking mode. I'd then say, “It's not quite right – change this, change that,” and we'd go back and forth three or four times. Then I'd edit the whole thing and put it into the text. So this book that I could have written on my own in a year, I wrote a first draft of with GPT-5 as my named co-author in two days. The whole project will take about six months from start to finish, and I'm having massive human editing – multiple edits from me, plus a professional editor. It's not a magic AI button. But I feel strongly about listing GPT-5 as a co-author because I've written it differently than previous books. I'm a huge believer in the old-fashioned lone author struggling and suffering – that's in my novels, and in Virtuoso I explore that. But other forms are going to emerge, just like video games are a creative, artistic form deeply connected to technology. The novel hasn't been around forever – the current format is only a few centuries old – and forms are always changing. There are real opportunities for authors, and there will be so much crap flooding the market because everybody can write something and put it up on Amazon. But I think there will be a very special place for thoughtful human authors who have an idea of what humans do at our best, and who translate that into content other humans can enjoy. Traditional vs Indie: Why This Book Will Be Self-Published Jo: I'm interested – you mentioned that it's your named co-author. Is this book going through a traditional publisher, and what do they think about that? Or are you going to publish it yourself? Jamie: It's such a smart question. What I found quickly is that when you get to be an author later in your career, you have all the infrastructure – a track record, a fantastic agent, all of that. But there were two things that were really important to me here: I wanted to get this book out really fast – six months instead of a year and a half. It was essential to me to have GPT-5 listed as my co-author, because if it were just my name, I feel like it would be dishonest. Readers who are used to reading my books – I didn't want to present something different than what it was. I spoke with my agent, who I absolutely love, and she said that for this particular project it was going to be really hard in traditional publishing. So I did a huge amount of research, because I'd never done anything in the self-publishing world before. I looked at different models. There was one hybrid model that's basically the same as traditional, but you pay for the things the publisher would normally pay for. I ended up not doing that. Instead, I decided on a self-publishing route where I disaggregated the publishing process. I found three teams: one for producing the book, one for getting the book out into the world, and a smaller one for the audiobook. I still believe in traditional publishing – there's a lot of wonderful human value-add. But some works just don't lend themselves to traditional publishing. For this book, which is called The AI Ten Commandments, that's the path I've chosen. Jo: And when's that out? I think people will be interested. Jamie: April 26th. Those of us used to traditional publishing think, “I've finished the book, sold the proposal, it'll be out any day now,” and then it can be a year and a half. It's frustrating. With this, the process can be much faster because it's possible to control more of the variables. But the key – as I was saying – is to make sure it's as good a book as everything else you've written. It's great to speed up, but you don't want to compromise on quality. The Coming Flood of Excellent AI-Generated Work Jo: Yeah, absolutely. We're almost out of time, but I want to come back to your “flood of crap” and the “AI slop” idea that's going around. Because you are working with GPT-5 – and I do as well, and I work with Claude and Gemini – and right now there are still issues. Like you said about referencing, there are still hallucinations, though fewer. But fast-forward two, five years: it's not a flood of crap. It's a flood of excellent. It's a flood of stuff that's better than us. Jamie: We're humans. It's better than us in certain ways. If you have farm machinery, it's better than us at certain aspects of farming. I'm a true humanist. I think there will be lots of things machines do better than us, but there will be tons of things we do better than them. There's a reason humans still care about chess, even though machines can beat humans at chess. Some people are saying things I fully disagree with, like this concept of AGI – artificial general intelligence – where machines do everything better than humans. I've summarised my position in seven letters: “AGI is BS.” The only way you can believe in AGI in that sense is if your concept of what a human is and what a human mind is is so narrow that you think it's just a narrow range of analytical skills. We are so much more than that. Humans represent almost four billion years of embodied evolution. There's so much about ourselves that we don't know. As incredible as these machines are and will become, there will always be wonderful things humans can do that are different from machines. What I always tell people is: whatever you're doing, don't be a second-rate machine. Be a first-rate human. If you're doing something and a machine is doing that thing much better than you, then shift to something where your unique capacities as a human give you the opportunity to do something better. So yes, I totally agree that the quality of AI-generated stuff will get better. But I think the most creative and successful humans will be the ones who say, “I recognise that this is creating new opportunities, and I'm going to insert my core humanity to do something magical and new.” People are “othering” these technologies, but the technologies themselves are magnificent human-generated artefacts. They're not alien UFOs that landed here. It's a scary moment for creatives, no doubt, because there are things all of us did in the past that machines can now do really well. But this is the moment where the most creative people ask themselves, “What does it mean for me to be a great human?” The pat answers won't apply. In my Virtuoso novel I explore that a lot. The idea that “machines don't do creativity” – they will do incredible creativity; it just won't be exactly human creativity. We will be potentially huge beneficiaries of these capabilities, but we really have to believe in and invest in the magic of our core humanity. Where to Find Jamie and His Books Jo: Brilliant. So where can people find you and your books online? Jamie: Thank you so much for asking. My website is jamiemetzl.com – and my books are available everywhere. Jo: Fantastic. Thanks so much for your time, Jamie. That was great. Jamie: Thank you, Joanna.The post Writing The Future, And Being More Human In An Age of AI With Jamie Metzl first appeared on The Creative Penn.